Latest news with #CollaborationandLicensingDeals
Business Wire
23-06-2025
- Business
- Business Wire
Artificial Intelligence (AI) Collaboration, R&D, and Licensing Agreements Trends Report 2025 with Directory of 959 Deals - Upfront, Milestone, & Royalties Terms, Company, Deal Type and Therapy Area
DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence (AI) Collaboration and Licensing Deals 2019-2025" has been added to offering. This report contains a comprehensive listing of 959 artificial intelligence deals announced since 2019, including financial terms where available, and links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Fully revised and updated, the report provides details of artificial intelligence deals from 2019 to 2025. Artificial Intelligence (AI) Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the artificial intelligence deals entered into by the world's leading biopharma companies. The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals. The initial chapters of the report offer an orientation of artificial intelligence dealmaking. It begins with an introduction, followed by an overview of the trends in AI dealmaking since 2019. The chapters then highlight leading AI deals, list the top 25 most active companies in AI dealmaking, and provide detailed reviews of AI deals and partnering agreements, organized by specific AI technology type and available contract documents. The report also includes numerous tables and figures that illustrate the trends and activities in artificial intelligence deal-making since 2019. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand. Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2019 Browse artificial intelligence collaboration and licensing deals Benchmark analysis - identify market value of transactions Financial terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess the suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Artificial Intelligence (AI) Collaboration and Licensing Deals includes: Trends in artificial intelligence dealmaking in the biopharma industry Directory of artificial intelligence deal records covering pharmaceutical and biotechnology The leading artificial intelligence deals by value Most active artificial intelligence licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in artificial intelligence dealmaking 2.1. Introduction 2.2. Artificial intelligence deals over the years 2.3. Most active artificial intelligence dealmakers 2.4. Artificial intelligence deals by deal type 2.5. Artificial intelligence deals by therapy area 2.6. Artificial intelligence deals by industry sector 2.7. Deal terms for artificial intelligence deals 2.7.1 Artificial intelligence deals headline values 2.7.2 Artificial intelligence deal upfront payments 2.7.3 Artificial intelligence deal milestone payments 2.7.4 Artificial intelligence royalty rates Chapter 3 - Leading artificial intelligence deals 3.1. Introduction 3.2. Top artificial intelligence deals by value Chapter 4 - Most active artificial intelligence dealmakers 4.1. Introduction 4.2. Most active artificial intelligence dealmakers 4.3. Most active artificial intelligence deals company profiles Chapter 5 - Artificial intelligence contracts dealmaking directory 5.1. Introduction 5.2. Artificial intelligence contracts dealmaking directory Chapter 6 - Artificial intelligence dealmaking by technology type Deal directory Deal directory - Artificial intelligence deals by company A-Z Deal directory - Artificial intelligence deals by deal type Deal directory - Artificial intelligence deals by therapy area Deal type definitions Companies Featured 3M ACT Therapeutics AdventHealth AbbVie Amgen Apple Inc. Alphabet Inc. Amazon Web Services General Electric IBM Microsoft Oracle Pfizer Tata Consultancy Services JP Morgan Chase Goldman Sachs Boeing Hewlett Packard Enterprise Procter & Gamble Johnson & Johnson Delta Air Lines Ford Motor Company Facebook NVIDIA Corporation Cisco Systems Intel Corporation Verizon Communications Coca-Cola Company Samsung Electronics Tesla, Inc. ExxonMobil Walmart PepsiCo Disney Adobe Systems Salesforce Nike Unilever Red Hat Siemens AG American Express Berkshire Hathaway Starbucks Alphabet Inc. Arm Holdings LinkedIn Airbnb Netflix Spotify SpaceX Uber Technologies For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Yahoo
17-06-2025
- Business
- Yahoo
Cancer Diagnostic Collaboration, R&D, and Licensing Deals Analysis Report 2025: Access Actual Deals Signed by the World's Leading Biopharma Companies Since 2018
Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostic Collaboration and Licensing Deals 2018-2025" report has been added to report contains a comprehensive listing of 724 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Fully revised and updated, the report provides details of cancer diagnostic deals from 2018 to 2025. The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the world's leading biopharma initial chapters of this report provide an orientation of cancer diagnostic 1 provides an introduction to the 2 provides an overview of the trends in cancer diagnostic dealmaking since 3 provides an overview of the leading cancer diagnostic deals since 2018. Deals are listed by headline 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2018, where a contract document is available in the public 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2018. The chapter is organized by specific cancer diagnostic technology type in report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2018 Browse cancer diagnostic collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Cancer Diagnostic Collaboration and Licensing Deals includes: Trends in cancer diagnostic dealmaking in the biopharma industry Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology The leading cancer diagnostic deals by value Most active cancer diagnostic licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in cancer diagnostic dealmaking2.1. Introduction2.2. Cancer diagnostic deals over the years2.3. Most active cancer diagnostic dealmakers2.4. Cancer diagnostic deals by deal type2.5. Cancer diagnostic deals by therapy area2.6. Cancer diagnostic deals by industry sector2.7. Deal terms for cancer diagnostic deals2.7.1 Cancer diagnostic deals headline values2.7.2 Cancer diagnostic deal upfront payments2.7.3 Cancer diagnostic deal milestone payments2.7.4 Cancer diagnostic royalty ratesChapter 3 - Leading cancer diagnostic deals3.1. Introduction3.2. Top cancer diagnostic deals by valueChapter 4 - Most active cancer diagnostic dealmakers4.1. Introduction4.2. Most active cancer diagnostic dealmakers4.3. Most active cancer diagnostic deals company profilesChapter 5 - Cancer diagnostic contracts dealmaking directory5.1. Introduction5.2. Cancer diagnostic contracts dealmaking directoryChapter 6 - Cancer diagnostic dealmaking by technology type For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
Cardiovascular Collaboration and Licensing Deals Report 2025: A Detailed Analysis of 589 Cardiovascular Deals from 2016 to 2025 - Key Players, Payments, and SEC Contracts Explored
The Cardiovascular Collaboration and Licensing Deals report details 589 biopharma agreements, analyzing financials, royalties, and deal structures. It includes links to actual contract documents, trends by therapeutic focus and technology, and insights into the most active dealmakers, offering critical benchmarking for future negotiations. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Cardiovascular Collaboration and Licensing Deals 2016-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cardiovascular deals entered into by the worlds leading biopharma revised and updated, the report provides details of 589 cardiovascular deals from 2016 to report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in cardiovascular 3 covers the financial deal terms for deals signed in the cardiovascular field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in cardiovascular dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of cardiovascular deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of cardiovascular deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in cardiovascular deal making since addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse cardiovascular collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeCardiovascular Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cardiovascular trends and structure of deals entered into by leading biopharma companies Collaboration and Licensing Deals includes: Trends in cardiovascular dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of cardiovascular deal records covering pharmaceutical and biotechnology The leading cardiovascular deals by value Most active cardiovascular licensing dealmakers In Cardiovascular Collaboration and Licensing Deals, the available deals are listed by: Company A-Z Headline value Therapeutic area Technology type Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in cardiovascular dealmaking2.1. Introduction2.2. Cardiovascular partnering over the years2.3. Cardiovascular partnering by deal type2.4. Cardiovascular partnering by industry sector2.5. Cardiovascular partnering by stage of development2.6. Cardiovascular partnering by technology type2.7. Cardiovascular partnering by therapeutic indicationChapter 3 - Financial deal terms for cardiovascular partnering3.1. Introduction3.2. Disclosed financials terms for cardiovascular partnering3.3. Cardiovascular partnering headline values3.4. Cardiovascular deal upfront payments3.5. Cardiovascular deal milestone payments3.6. Cardiovascular royalty ratesChapter 4 - Leading cardiovascular deals and dealmakers4.1. Introduction4.2. Most active in cardiovascular partnering4.3. List of most active dealmakers in cardiovascular4.4. Top cardiovascular deals by valueChapter 5 - Cardiovascular contract document directory5.1. Introduction5.2. Cardiovascular partnering deals where contract document availableChapter 6 - Cardiovascular dealmaking by therapeutic target6.1. Introduction6.2. Deals by cardiovascular therapeutic targetDeal directory Deal directory - Cardiovascular deals by company A-Z 2016 to 2025 Deal directory - Cardiovascular deals by technology type 2016 to 2025 For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
Global Oncology Collaboration and Licensing Deals Report 2020-2025: 3,350 Biopharma Agreements Analyzed with Financial Terms, Partnering Trends, and Contract Insights
Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2020-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma revised and updated, the report provides details of 3,350 oncology deals from 2020 to 2025. Oncology Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2020 Browse oncology collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? 2,954 companies are featured in the report, including (sorted a-z): 1ST Biotherapeutics 2cureX 2seventy bio 3B Pharmaceuticals 3D Medicines 3SBio 3T Biosciences 4baseCare 4bases 4C Biomed 4D Path 4D Pharma 7 Hills Pharma 9 Meters Biopharma 48Hour Discovery 111 A*STAR Agency for Science Technology and Research A*STAR Bioprocessing Technology Institute A*STAR Singapore Immunology Network A*STAR' Institute of Molecular and Cell Biology A2 Biotherapeutics A2A Pharmaceuticals A3P Biomedical Aadi Bioscience Aarvik Therapeutics Abbisko Therapeutics Abbott Laboratories Abbvie Abcam AbCellera Biologics Abdul Latif Jameel Health AbelZeta Pharma Abera Bioscience Abilita Bio Abilita Therapeutics Abintus Bio Abiosciences Ablaze Pharmaceuticals ABL Bio Ab Magnitude Ventures Abound Bio Abpro Abramson Cancer Center AbSci AbTherx AbTis ABVC BioPharma Abveris ABX Academic Breast Cancer Consortium Accelerated Biosciences Accent Therapeutics Access to Comprehensive Genomic Profiling Coalition Acclinate Accuray AccuStem Sciences ACEA Therapeutics Acepodia Acerand Therapeutics Acerta Pharma Achilles Therapeutics Acibadem University Acrivon Therapeutics Acrotech Biopharma Actimed Therapeutics Actinium Pharmaceuticals ACT Therapeutics Actuate Therapeutics Acucela Acuitas Therapeutics Adagene AdAlta Adamis Pharmaceuticals Adaptimmune Adaptive Biotechnologies Adaptive Research AdaptVac Adcendo ADC Therapeutics Addario Lung Cancer Medical Institute AdhereTech Adimab Adlai Nortye Advancell Advaxis Advenchen Laboratories Aerogen Aethlon Medical Aethon Therapeutics Aetion Affimed Therapeutics Affini-T Therapeutics AGC Biologics Agena Bioscience Agencja Badan Medycznych Agendia Agenus Bio AgeX Therapeutics Agilent Technologies Agios Pharmaceuticals AgonOx AiCure Aidence Aidoc Aignostics AIkido Pharma AI Longevity AimedBio AIM ImmunoTech Ainos Aion Therapeutic AI Proteins Aitia AiVita Biomedical Ajax Therapeutics Ajinomoto Akamis Bio Akeso Biopharma Akoya Biosciences AKSO Biopharmaceutical Akston Biosciences Aktis Oncology Alamar Biosciences Albany Medical College Alberta Health Services Albert Einstein College of Medicine Alcedis Alchemab Alector Alessa Therapeutics Aleta Biotherapeutics Alex's Lemonade Stand Foundation Alibaba Health ALK Positive Alkyon Therapeutics All4Cure Allarity Therapeutics Allcyte Allelica Alliance for Cancer Gene Therapy Alliance Foundation Trials Alligator Bioscience Allist Pharma Allogene Overland Biopharm Allogene Therapeutics Alloplex Biotherapeutics Allorion Therapeutics Alloy Therapeutics Almac Diagnostics Almac Group Almirall Alopexx Alpha Biopharma Alpha Cancer Technologies Alphageneron Pharmaceuticals Alphamab Biopharmaceuticals Alphamab Oncology Alpha Tau Medical Alpine Immune Sciences Alteogen Alverno Clinical Laboratories Alvotech ALX Oncology Amasa Therapeutics Amazon Web Services Amber Pharmacy Ambry Genetics American Association for Cancer Research American Lung Association American Preclinical Services American Skin Association American Society of Clinical Oncology (ASCO) American Type Culture Collection (ATCC) Amgen AmMax Bio Amneal Pharmaceuticals Amoy Diagnostics Amphista Therapeutics AmplifyBio Amunix AnchorDx Angiogenesis Foundation Angle AnHeart Therapeutics Anima Biotech Anivive Lifesciences Anixa Biosciences Anji Pharma Anju Software Ankarys Therapeutics Ankyra Therapeutics Anocca AB Anova Enterprises Anpac Bio-Medical Science ANP Technologies Antengene Anthony Nolan Antisoma Therapeutics Antiverse Apeiron Biologics Apexigen Apmonia Therapeutics Apollomics Apollon Formularies Apollo Therapeutics Appia Bio Applied BioMath For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
